Mirtazapine antagonises the subjective, hormonal and neuronal effects of m-chlorophenylpiperazine (mCPP) infusion: A pharmacological-challenge fMRI (phMRI) study

NeuroImage

Volumn 58, Issue 2, 2011, Pages 497-507

  McKie, Shane ^a   Richardson, Paul ^b   Elliott, Rebecca ^a   Völlm, Birgit A ^c   Dolan, Mairead C ^d   Williams, Steve R ^a   Anderson, Ian M ^a   Deakin, J F William ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

Author keywords

5 HT2c; Cortisol; M Chlorophenylpiperazine (mCPP); Mirtazapine; Pharmacological challenge fMRI (phMRI); Subjective effects

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; MIRTAZAPINE; PLACEBO; SEROTONIN 2C RECEPTOR;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BOLD SIGNAL; BRAIN; CAUDATE NUCLEUS; CHOROID PLEXUS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLOBUS PALLIDUS; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS; MALE; MORNING DOSAGE; NORMAL HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBSTANTIA NIGRA;

ADULT; BRAIN; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; HORMONES; HUMANS; HYDROCORTISONE; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIANSERIN; OXYGEN; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; YOUNG ADULT;

EID: 80051792555     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.06.049     Document Type: Article

References (49)

1. Abramowski D., Rigo M., Duc D., Hoyer D., Staufenbiel M. Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 1995, 34:1635-1645.
2. Ammons R.B., Ammons C.H. Quick Test 1962, Psychological Test Specialists, Missoula.
3. Anderson I.M., Clark L., Elliott R., Kulkarni B., Williams S.R., Deakin J.F. 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport 2002, 13:1547-1551.
4. Anderson I.M., McKie S., Elliott R., Williams S.R., Deakin J.F. Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology 2008, 55:1029-1037.
5. Baxter G., Kennett G., Blaney F., Blackburn T. 5-HT2 receptor subtypes: a family re-united?. Trends Pharmacol. Sci. 1995, 16:105-110.
6. Caccia S., Ballabio M., Samanin R., Zanini M.G., Garattini S. (--)-m-Chlorophenyl-piperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J. Pharm. Pharmacol. 1981, 33:477-478.
7. Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987, 92:14-24.
8. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int. Clin. Psychopharmacol. 1995, 10(Suppl 4):19-23.
9. de Leeuw A.S., Westenberg H.G. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. J. Psychiatr. Res. 2008, 42:894-901.
10. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry 2008, 65:154-164.
11. Di Matteo V., De Blasi A., Di Giulio C., Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol. Sci. 2001, 22:229-232.
12. Di Matteo V., Cacchio M., Di Giulio C., Esposito E. Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol. Biochem. Behav. 2002, 71:727-734.
13. Fiorella D., Helsley S., Rabin R.A., Winter J.C. 5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berl) 1995, 122:237-243.
14. Fiorella D., Rabin R.A., Winter J.C. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berl) 1995, 119:222-230.
15. Forutan F., Estalji S., Beu M., Nikolaus S., Hamacher K., Coenen H.H., Vosberg H., Muller-Gartner H.W., Larisch R. Distribution of 5HT2A receptors in the human brain: comparison of data in vivo and post mortem. Nuklearmedizin 2002, 41:197-201.
16. Franklin M. Determination of nefazodone and its metabolites in plasma by high-performance liquid chromatography with coulometric detection. J. Pharm. Biomed. Anal. 1993, 11:1109-1113.
17. Germine M., Goddard A.W., Sholomskas D.E., Woods S.W., Charney D.S., Heninger G.R. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res. 1994, 54:115-133.
18. Gijsman H.J., Cohen A.F., van Gerven J.M. The application of the principles of clinical drug development to pharmacological challenge tests of the serotonergic system. J. Psychopharmacol. 2004, 18:7-13.
19. Giorgetti M., Tecott L.H. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur. J. Pharmacol. 2004, 488:1-9.
20. Hackler E.A., Turner G.H., Gresch P.J., Sengupta S., Deutch A.Y., Avison M.J., Gore J.C., Sanders-Bush E. 5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. J. Pharmacol. Exp. Ther. 2007, 320:1023-1029.
21. Hamik A., Peroutka S.J. 1-(M-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol. Psychiatry 1989, 25:569-575.
22. Hinz R., Bhagwagar Z., Cowen P.J., Cunningham V.J., Grasby P.M. Validation of a tracer kinetic model for the quantification of 5-HT(2A) receptors in human brain with [(11)C]MDL 100,907. J. Cereb. Blood Flow Metab. 2007, 27:161-172.
23. Hommer D., Andreasen P., Rio D., Williams W., Ruttimann U., Momenan R., Zametkin A., Rawlings R., Linnoila M. Effects of m-chlorophenylpiperazine on regional brain glucose utilization: a positron emission tomographic comparison of alcoholic and control subjects. J. Neurosci. 1997, 17:2796-2806.
24. Kahn R.S., Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol. Psychiatry 1991, 30:1139-1166.
25. Kaufman M.J., Hartig P.R., Hoffman B.J. Serotonin 5-HT2C receptor stimulates cyclic GMP formation in choroid plexus. J. Neurochem. 1995, 64:199-205.
26. Lopez-Gimenez J.F., Tecott L.H., Palacios J.M., Mengod G., Vilaro M.T. Serotonin 5- HT (2C) receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. J. Neurosci. Res. 2002, 67:69-85.
27. Marazziti D., Rossi A., Giannaccini G., Zavaglia K.M., Dell'Osso L., Lucacchini A., Cassano G.B. Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur. Neuropsychopharmacol. 1999, 10:21-26.
28. McKie S., Del-Ben C., Elliott R., Williams S., del Vai N., Anderson I., Deakin J.F. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl) 2005, 180:680-686.
29. Middlemiss D.N., Hutson P.H. The 5-HT1B receptors. Ann. N. Y. Acad. Sci. 1990, 600:132-147. (discussion 347-148).
30. Millan M.J., Gobert A., Rivet J.M., Adhumeau-Auclair A., Cussac D., Newman-Tancredi A., Dekeyne A., Nicolas J.P., Lejeune F. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur. J. Neurosci. 2000, 12:1079-1095.
31. Murphy D.L., Mueller E.A., Hill J.L., Tolliver T.J., Jacobsen F.M. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology (Berl) 1989, 98:275-282.
32. Pasqualetti M., Ori M., Castagna M., Marazziti D., Cassano G.B., Nardi I. Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 1999, 92:601-611.
33. Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain-III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 1987, 21:97-122.
34. Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987, 21:123-139.
35. Pigott T.A., Zohar J., Hill J.L., Bernstein S.E., Grover G.N., Zohar-Kadouch R.C., Murphy D.L. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol. Psychiatry 1991, 29:418-426.
36. Rotzinger S., Fang J., Coutts R.T., Baker G.B. Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol. Psychiatry 1998, 44:1185-1191.
37. Seibyl J.P., Krystal J.H., Price L.H., Woods S.W., D'Amico C., Heninger G.R., Charney D.S. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res. 1991, 38:227-236.
38. Seminowicz D.A., Mayberg H.S., McIntosh A.R., Goldapple K., Kennedy S., Segal Z., Rafi-Tari S. Limbic-frontal circuitry in major depression: a path modeling metanalysis. NeuroImage 2004, 22:409-418.
39. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33. (quiz 34-57).
40. Siever L.J., Buchsbaum M.S., New A.S., Spiegel-Cohen J., Wei T., Hazlett E.A., Sevin E., Nunn M., Mitropoulou V. d, l-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology 1999, 20:413-423.
41. Silverstone P.H., Rue J.E., Franklin M., Hallis K., Camplin G., Laver D., Cowen P.J. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. Int. Clin. Psychopharmacol. 1994, 9:173-178.
42. Singewald N., Salchner P., Sharp T. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol. Psychiatry 2003, 53:275-283.
43. Stark J.A., Davies K.E., Williams S.R., Luckman S.M. Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. NeuroImage 2006, 31:1228-1237.
44. Stark J.A., McKie S., Davies K.E., Williams S.R., Luckman S.M. 5-HT(2C) antagonism blocks blood oxygen level-dependent pharmacological-challenge magnetic resonance imaging signal in rat brain areas related to feeding. Eur. J. Neurosci. 2008, 27:457-465.
45. Stimmel G.L., Dopheide J.A., Stahl S.M. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997, 17:10-21.
46. Talairach J., Tournoux P. Co-planar stereotaxic atlas of the human brain 1988, Thieme, New York.
47. Thomas D.R., Gager T.L., Holland V., Brown A.M., Wood M.D. m-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor. Neuroreport 1996, 7:1457-1460.
48. Timmer C.J., Sitsen J.M., Delbressine L.P. Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. 2000, 38:461-474.
49. Voortman G., Paanakker J.E. Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Hum. Psychopharmacol. 1995, 10:83-96.